Physician profile
Mark A Truax
NPI 1508802273
$2,311.62
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $283 · 2021: $480 · 2022: $17.06.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $298.59 | 2019-2021 | |
| Novo Nordisk INC | $211.18 | 2019-2021 | |
| Amgen INC. | $209.02 | 2019 | |
| Lilly USA, LLC | $203.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $203.00 | 2019-2021 | |
| Allergan, INC. | $157.30 | 2019-2020 | |
| Astellas Pharma US INC | $148.70 | 2019-2020 | |
| Abbvie INC. | $147.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $143.27 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $126.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.59 | 2021 | |
| Glaxosmithkline, LLC. | $36.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $25.11 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $22.64 | 2019 | |
| Mylan Specialty L.P. | $16.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.83 | 2019 | |
| Shire North American Group INC | $15.13 | 2019 | |
| Currax Pharmaceuticals LLC | $14.87 | 2020 | |
| Adlon Therapeutics L.P. | $14.83 | 2020 | |
| Bausch Health US, LLC | $14.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.06 | 2019 | |
| Circassia INC. | $11.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.46 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Truax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.